Want to see RNTX full AI Analyst Report?
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$0.86 - $2.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$84.81M
Enterprise Value$24.66M
Total Cash (Recent Filing)$4.45M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta1.28
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding85,539,030
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.15
Forecast
1Y Price Target
$8.00Price Target Upside534.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Funding RunwayThe $50M equity offering extends the company’s operating runway into 2028, materially lowering near-term liquidity risk. That durable capital visibility allows management to complete the Phase 2 LTI-03 program and other R&D activities without immediate refinancing, supporting steady clinical execution and reducing short-term funding distraction.
Investor Alignment Via Bios PartnersThe deferment and lock-up by a key investor aligns major stakeholders with the company’s long-term capital plan and reduces potential near-term share overhang. This structural agreement stabilizes the cap table through 2029, lowering governance and secondary selling risk during pivotal clinical development years.
Focused Clinical-stage PipelineA concentrated R&D focus on pulmonary diseases and a funded Phase 2 program for LTI-03 creates a clear strategic thesis. This specialized pipeline offers a durable corporate identity and potential high-impact clinical inflection points that, if successful, could sustainably transform revenue prospects and partnership opportunities.
Bears Say
No Revenue; Large Net LossesThe company reports no product or recurring revenue while posting a TTM net loss of $50.2M. Persistent pre-revenue losses create a structural dependence on external capital and heighten execution risk: without successful trial outcomes or licensing, the firm cannot self-fund development or cover operating needs long term.
Negative Cash GenerationOperating and free cash flow remain negative at -$16.6M TTM despite some improvement versus prior years. Ongoing cash burn constrains the company’s ability to fund trials internally, increases reliance on dilutive financing, and injects persistent refinancing risk that can delay programs or force unfavorable partnership terms.
Shrinking Equity Base; Dilution RiskShareholders’ equity has contracted significantly, reducing balance-sheet cushioning against operational shocks. Coupled with large recent equity issuance and ongoing losses, this structural erosion raises the probability of further dilution and limits financial flexibility, which can hamper strategic choices and increase long-term financing costs.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $0.86 and its highest was $2.18 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $84.81M.
When is Rein Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rein Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 85,539,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (534.92% Upside)
$8.00 (534.92% Upside)
Insider Transactions
Bought Shares
Worth $74.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
-258.45%
Trailing 12-Months
Asset Growth
-54.38%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
RNTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(534.92% Upside)
Technical Analysis
Ownership Overview
1.78% Insiders
1.38% Mutual Funds
11.00% Other Institutional Investors
83.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---